Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL

M. van Gelder*, O. Tournilhac, D. te Raa, H.P.J. Visser

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademicpeer-review

Original languageEnglish
Pages (from-to)1442-1443
Number of pages2
JournalAnnals of Oncology
Issue number11
Publication statusPublished - 1 Nov 2021

Cite this